Collaborative Arrangement, Milestones Payable

No definition available.

Name:	imdz_CollaborativeArrangementMilestonesPayable
Namespace Prefix:	imdz_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Number of License Agreements

+ References

No definition available.

+ Details

Name:	imdz_NumberofLicenseAgreements
Namespace Prefix:	imdz_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	instant

- Definition

Revenue Recognition, Milestone Method, Milestones Receivable

+ References

No definition available.

+ Details

Name:	imdz_RevenueRecognitionMilestoneMethodMilestonesReceivable
Namespace Prefix:	imdz_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

For unclassified balance sheet, amounts due from customers or clients for goods or services that have been delivered or sold in the normal course of business.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 3

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-03.9)

-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

+ Details

Name:	us-gaap_AccountsReceivableGross
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section A

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.A.4(a).Q1 Response)

-URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780

+ Details

Name:	us-gaap_DeferredRevenue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 985

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 730

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

+ Details

Name:	us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The amount of consideration recognized during the period for the milestone or milestones.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 28

-Section 50

-Paragraph 2

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=19771982&loc=SL6892177-166501

+ Details

Name:	us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Value of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.

+ References

No definition available.

+ Details

Name:	us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Details

Name:	us-gaap_IncomeStatementLocationAxis=imdz_CollaborationRevenueMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_IncomeStatementLocationAxis=imdz_LicenseRevenueMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_IncomeStatementLocationAxis=imdz_OtherRevenueMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ProductOrServiceAxis=imdz_DendriticCelltargetedTheraputicandProphylacticImmunizationStrategiesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ProductOrServiceAxis=imdz_GLAASDiscoveryPlatformMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ProductOrServiceAxis=imdz_GLAFirstProductMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ProductOrServiceAxis=imdz_GLAProductMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ProductOrServiceAxis=imdz_GLASubsequentProductsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ProductOrServiceAxis=imdz_HerpesSimplexVirusImmuneTherapyMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

License and Collaboration Agreements - Narrative (Details) (USD $)	12 Months Ended			1 Months Ended	51 Months Ended	8 Months Ended	1 Months Ended	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Aug. 31, 2014	Dec. 31, 2014	Dec. 31, 2013	Jul. 31, 2008	Dec. 31, 2009	Oct. 31, 2010 license_agreement
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Research and development	$ 22,746,000us-gaap_ResearchAndDevelopmentExpense	$ 11,554,000us-gaap_ResearchAndDevelopmentExpense	$ 8,604,000us-gaap_ResearchAndDevelopmentExpense
GLAAS Discovery Platform [Member] \| Collaborative Arrangement, Product [Member] \| Sanofi [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Milestone revenue recognized				3,500,000
Milestone receivables				168,000,000
GLA [Member] \| Collaborative Arrangement, Product [Member] \| MedImmune LLC [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Milestone revenue recognized	1,000,000				5,500,000
Number of license agreements									3
GLA [Member] \| Collaborative Arrangement, Product [Member] \| MedImmune LLC [Member] \| Minimum [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Milestone receivables	62,900,000				62,900,000
GLA [Member] \| Collaborative Arrangement, Product [Member] \| MedImmune LLC [Member] \| Maximum [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Milestone receivables	75,000,000				75,000,000
GLA [Member] \| Collaborative Arrangement, Product [Member] \| Medicago Inc [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Milestone revenue recognized						500,000
Milestone receivables	9,500,000				9,500,000
GLA [Member] \| Collaborative Arrangement [Member] \| Infectious Disease Research Institute [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Research and development	1,900,000	140,000
GLA [Member] \| Collaborative Arrangement [Member] \| Infectious Disease Research Institute [Member] \| Common stock [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Value of common stock issued for license							59,000
First GLA Product [Member] \| Collaborative Arrangement [Member] \| Infectious Disease Research Institute [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Potential future milestone payments	2,400,000				2,400,000
Subsequent GLA Products [Member] \| Collaborative Arrangement [Member] \| Infectious Disease Research Institute [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Potential future milestone payments	1,300,000				1,300,000
Dendritic Cell-targeted Theraputic and Prophylactic Immunization Strategies [Member] \| Collaborative Arrangement [Member] \| California Institute of Technology [Member] \| Common stock [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Value of common stock issued for license								25,000
Potential future milestone payments	1,600,000				1,600,000
Herpes Simplex Virus Immune Therapy [Member] \| Collaborative Arrangement, Product [Member] \| Sanofi [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Accounts Receivable, Gross	1,500,000				1,500,000
Deferred Revenue	492,000				492,000
License Revenue [Member] \| GLA [Member] \| Collaborative Arrangement, Product [Member] \| Sanofi [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Milestone revenue recognized			805,000
Other Revenue [Member] \| GLA [Member] \| Collaborative Arrangement, Product [Member] \| Sanofi [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Milestone revenue recognized			200,000
Collaboration Revenue [Member] \| Herpes Simplex Virus Immune Therapy [Member] \| Collaborative Arrangement, Product [Member] \| Sanofi [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Milestone revenue recognized	$ 1,100,000